Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

Cydan spins out rare endocrine company Tiburio with $31M, Ipsen compounds

Jennie Walters
January 3, 2019 12:06 PM UTC

Tiburio Therapeutics Inc. (Cambridge, Mass.) launched Thursday with a $31 million series A round and two clinical compounds licensed from Ipsen Group (Euronext:IPN; Pink:IPSEY) that it plans to develop for rare neuroendocrine tumors and rare endocrine diseases.

Tiburio spun out of Cydan Development Inc. (Cambridge, Mass.), which creates companies to de-risk and develop assets sourced from academia, not-for-profits and industry. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Cydan II Inc.